Multi-omic profiling reveals early immunological indicators for identifying COVID-19 Progressors.
COVID19
Early infection
Multi-omic analysis
SARS-CoV-2
Systems immunology
Journal
Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
26
07
2023
revised:
25
09
2023
accepted:
11
10
2023
medline:
6
11
2023
pubmed:
19
10
2023
entrez:
18
10
2023
Statut:
ppublish
Résumé
We sought to better understand the immune response during the immediate post-diagnosis phase of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by identifying molecular associations with longitudinal disease outcomes. Multi-omic analyses identified differences in immune cell composition, cytokine levels, and cell subset-specific transcriptomic and epigenomic signatures between individuals on a more serious disease trajectory (Progressors) as compared to those on a milder course (Non-progressors). Higher levels of multiple cytokines were observed in Progressors, with IL-6 showing the largest difference. Blood monocyte cell subsets were also skewed, showing a comparative decrease in non-classical CD14
Identifiants
pubmed: 37852344
pii: S1521-6616(23)00571-5
doi: 10.1016/j.clim.2023.109808
pii:
doi:
Substances chimiques
Cytokines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
109808Investigateurs
Chen Chen
(C)
Sairam Parthasarathy
(S)
Victor F Tapson
(VF)
James N Moy
(JN)
Christopher R de Filippi
(CR)
Ivan O Rosas
(IO)
Mujeeb Basit
(M)
Mirella Salvatore
(M)
Jerry A Krishnan
(JA)
Commentaires et corrections
Type : UpdateOf
Informations de copyright
Copyright © 2023 Verily Life Sciences LLC. Published by Elsevier Inc. All rights reserved.